Merck said Lynparza (olaparib), a targeted therapy co-developed with AstraZeneca, has become the first PARP inhibitor approved by the Food and Drug Administration for treating metastatic breast cancer.
To boost support for caregivers on an international scale, Merck KGaA of Darmstadt, Germany, launched a worldwide program called Embracing Carers and presented recent survey results at a conference in Australia.
Dupixent (dupilumab), a medication jointly marketed by Sanofi and Regeneron Pharmaceuticals for relieving a form of eczema known as atopic dermatitis (AD) in adults, recently received marketing approval in the European Union (EU).
With relatively little known about suicide from a genetic standpoint and its prevalence among youth fatalities in Utah, University of Utah Health has collaborated with Janssen Research & Development on the Utah Suicide Genetics Project.
A Phase 3 CHRONOS test from Sanofi and Regeneron Pharmaceuticals of the drug Dupixent shows promise in patients with uncontrolled moderate to severe atopic dermatitis when used with a topical corticosteroid.
Newly released results from an international Phase 3 clinical trial show Xultophy 100/3.6, a new treatment for diabetes developed by Novo Nordisk Inc. is more effective than traditional insulin alone and eliminates some insulin side effects.
Patients suffering from triple negative breast cancer, a treatment-resistant form of the disease, have a new option in pembrolizumab, a drug manufactured by Merck that was previously FDA-authorized for other malignancies.
Bristol-Myers Squibb said it will collaborate with Advaxis Inc. in a study to evaluate ADXS-DUAL and Opdivo (nivolumab) in a combination therapy for cervical cancer that has resisted or recurred after chemotherapy.